SylA-LIP

SylA-LIP is a synthetic lipophilic analog of syringolin A (SylA), a member of the syrbactin class of proteasome inhibitors. Syrbactins, which also include glidobactins, are natural products and their derivatives that inhibit the eukaryotic 20S proteasome through a unique covalent mechanism involving the catalytic N-terminal threonine residues. SylA-LIP was developed to explore the therapeutic potential of syrbactins in oncology, specifically targeting the chymotrypsin-like activity of the proteasome. Preclinical research has demonstrated that SylA-LIP inhibits cell proliferation and induces apoptosis and autophagy in various cancer models, including neuroblastoma, multiple myeloma, and ovarian cancer cells.

Other names

syringolin A lipophilic analog